TY - JOUR
T1 - The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
AU - Alomari, Mohammed
AU - Kunacheewa, Chutima
AU - Manasanch, Elisabet E.
N1 - Funding Information:
This work was supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society Specialized Center of Research (LLS SCOR), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Paula and Rodger Riney Foundation, and the University of Texas MD Anderson Moon Shot Program.
Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Currently used stratification models in myeloma precursor disease as well as staging systems and response criteria in myeloma have limitations including failure to identify functionally high-risk myeloma patients. B-cell maturation antigen, a transmembrane glycoprotein required for long-lived plasma cells, is specific and expressed by myeloma cells. When it sheds from the surface of myeloma cells it can be measured in the blood as serum (sBCMA) and correlated with clinical outcomes in myeloma precursor disease as well as in active myeloma. We performed a literature review using PubMed and found 825 articles since 1992 of which any articles related to sBCMA were reviewed. These studies show the potential of sBCMA to become an important biomarker in myeloma. Here, we describe the potential advantages of sBCMA in the biology, diagnosis, prognosis, and surveillance of myeloma, while also reviewing the challenges that lie ahead before it can be implemented as a clinical tool.
AB - Currently used stratification models in myeloma precursor disease as well as staging systems and response criteria in myeloma have limitations including failure to identify functionally high-risk myeloma patients. B-cell maturation antigen, a transmembrane glycoprotein required for long-lived plasma cells, is specific and expressed by myeloma cells. When it sheds from the surface of myeloma cells it can be measured in the blood as serum (sBCMA) and correlated with clinical outcomes in myeloma precursor disease as well as in active myeloma. We performed a literature review using PubMed and found 825 articles since 1992 of which any articles related to sBCMA were reviewed. These studies show the potential of sBCMA to become an important biomarker in myeloma. Here, we describe the potential advantages of sBCMA in the biology, diagnosis, prognosis, and surveillance of myeloma, while also reviewing the challenges that lie ahead before it can be implemented as a clinical tool.
KW - BCMA-directed therapy
KW - biomarker
KW - multiple myeloma
KW - sBCMA
UR - http://www.scopus.com/inward/record.url?scp=85141135045&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141135045&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2133540
DO - 10.1080/10428194.2022.2133540
M3 - Review article
C2 - 36282671
AN - SCOPUS:85141135045
SN - 1042-8194
VL - 64
SP - 261
EP - 272
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -